RET (Y806N)

RET · Variant type: point · HGVS: p.Y806N

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pralsetinib	95.1%	4.9%	93.43
2	Selpercatinib	95.0%	5.0%	96.72
3	Sorafenib	84.2%	15.8%	96.72
4	Tivozanib	84.2%	15.8%	92.42
5	Fedratinib	69.0%	30.9%	96.21
6	Apatinib	67.2%	32.8%	97.73
7	Tenalisib	55.5%	44.5%	97.98
8	Entrectinib	42.6%	57.4%	93.69
9	Alpelisib	42.1%	57.9%	97.22
10	Gilteritinib	23.4%	76.6%	88.97
11	Vandetanib	14.6%	85.4%	95.74
12	Quizartinib	12.8%	87.2%	99.50
13	Erdafitinib	12.4%	87.6%	95.71
14	Canertinib	10.5%	89.5%	96.49
15	Defactinib	8.6%	91.4%	92.68
16	Erlotinib	8.1%	91.9%	99.75
17	Mobocertinib	7.0%	93.0%	97.22
18	Futibatinib	6.6%	93.4%	98.48
19	Pacritinib	5.1%	94.9%	88.64
20	Pirtobrutinib	4.3%	95.7%	99.49
21	Pemigatinib	4.0%	96.0%	98.23
22	Acalabrutinib	3.8%	96.2%	99.50
23	Darovasertib	3.7%	96.3%	96.99
24	Avapritinib	3.1%	96.9%	97.73
25	Ripretinib	3.0%	97.0%	92.95

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pralsetinib	95.1%	100.0%	-4.9%
Selpercatinib	95.0%	100.0%	-5.0%
Sorafenib	84.2%	94.0%	-9.7%
Tivozanib	84.2%	99.7%	-15.5%
Fedratinib	69.0%	99.9%	-30.8%
Apatinib	67.2%	—	—
Tenalisib	55.5%	98.5%	-43.0%
Entrectinib	42.6%	99.6%	-57.0%
Alpelisib	42.1%	99.6%	-57.5%
Gilteritinib	23.4%	100.0%	-76.6%
Vandetanib	14.6%	98.6%	-84.0%
Quizartinib	12.8%	—	—
Erdafitinib	12.4%	94.7%	-82.3%
Canertinib	10.5%	—	—
Defactinib	8.6%	—	—
Erlotinib	8.1%	—	—
Mobocertinib	7.0%	—	—
Futibatinib	6.6%	97.7%	-91.1%
Pacritinib	5.1%	—	—
Pirtobrutinib	4.3%	—	—
Pemigatinib	4.0%	—	—
Acalabrutinib	3.8%	—	—
Darovasertib	3.7%	—	—
Avapritinib	3.1%	—	—
Ripretinib	3.0%	—	—

Cancer	Organ	Source
carcinoma_thyroid	Thyroid	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.8ms